Last reviewed · How we verify
Romosozumab followed by Denosumab
Romosozumab stimulates bone formation via Wnt signaling inhibition, followed by Denosumab which blocks osteoclast-mediated bone resorption, providing sequential anabolic then anti-catabolic therapy for osteoporosis.
Romosozumab stimulates bone formation via Wnt signaling inhibition, followed by Denosumab which blocks osteoclast-mediated bone resorption, providing sequential anabolic then anti-catabolic therapy for osteoporosis. Used for Osteoporosis in postmenopausal women at high risk of fracture.
At a glance
| Generic name | Romosozumab followed by Denosumab |
|---|---|
| Also known as | Sequential therapy group |
| Sponsor | National Taiwan University Hospital |
| Drug class | Sclerostin inhibitor followed by RANKL inhibitor |
| Target | Sclerostin (romosozumab); RANKL (Denosumab) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Romosozumab is a sclerostin inhibitor that promotes osteoblast activity and new bone formation while transiently reducing bone resorption. Denosumab is a RANKL inhibitor that potently suppresses osteoclast differentiation and function, reducing bone turnover. This sequential approach leverages the anabolic phase of romosozumab followed by sustained anti-resorptive effects of denosumab to maximize bone mineral density gains and fracture risk reduction.
Approved indications
- Osteoporosis in postmenopausal women at high risk of fracture
Common side effects
- Injection site reactions
- Hypocalcemia
- Arthralgia
- Headache
- Osteonecrosis of the jaw (rare)
Key clinical trials
- Romosozumab/Denosumab Study for Premenopausal IOP (PHASE2)
- Contribution of Bone to Urine Citrate
- Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients (PHASE4)
- Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI (PHASE4)
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (PHASE2)
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: